

Attorney Dkt. No. 51275/149

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
VIA FACSIMILERECEIVED
CENTRAL FAX CENTER

In re: application of:
Theoharis C. Theoharides
Filing date: 03/20/2004
Serial No.: 10/811,828
Priority from copending PCT/US02/00476, filed 01/03/2002,
copending USSN 09/771,669, filed 01/30/2001, and USSN 09/056,707, filed
4/8/1998, now USPN 6,689,748, issued 2/10/2004
For: Composition For Protection Against Superficial Vasodilator Flush Syndrome

APR 12 2007
Group Art Unit: 1655
Examiner: Patricia Leith

Response to Notice of Abandonment

Commissioner for Patents
Box 1450
Alexandria, VA 22313-1450
Mail Stop: Non-fee Amendment

Sir:

In an Action mailed 04/10/2007, the Examiner issued a Notice of Abandonment for an alleged failure to respond to Examiner's 08/28/2006 Office Action.

The Examiner appears not to be aware that the Office Actions of 08/28/2006 and 05/04/2006, both concerning a restriction requirement, were responded to by a Petition to the Director, dated 10/09/2006. A copy of the Petition and acknowledgement of receipt by the Office are enclosed. This Petition has not yet been acted upon. Until the Director adjudicates the issue, it is the undersigned's opinion that a response to the 08/28/2006 Office Action is held in obeyance. Please correct me if my opinion is incorrect.

Respectfully submitted,



Dr. Melvin Blecher
Attorney-at-Law
Registration No. 33,649

04/12/2007

Law Offices of Dr. Melvin Blecher
4329 Van Ness St., NW
Washington, DC 20016-5625
Tel: 202 363 3338/0373

FAX: 202 362 8404
e-mail: MBiplaw@comcast.net

USPTO

10/9/2006 1:40:27 PM PAGE 1/001 Fax Server

TO: Auto-reply fax to 2023628404 COMPANY:

RECEIVED
CENTRAL FAX CENTER

APR 12 2007

Auto-Reply Facsimile Transmission



TO: Fax Sender at 2023628404

Fax Information
 Date Received: 10/9/2006 1:38:00 PM [Eastern Daylight Time]
 Total Pages: 3 (including cover page)

ADVISORY: This is an automatically generated return receipt confirmation of the facsimile transmission received by the Office. Please check to make sure that the number of pages listed as received in Total Pages above matches what was intended to be sent. Applicants are advised to retain this receipt in the unlikely event that proof of this facsimile transmission is necessary. Applicants are also advised to use the certificate of facsimile transmission procedures set forth in 37 CFR 1.8(e) and (b), 37 CFR 1.6(f). Trademark Applicants, also see the Trademark Manual of Examining Procedure (TMEP) section 306 et seq.

Received
 Cover
 Page
 =====>

10/09/2006 09:22 2023628404	MBIPLAW	PAGE 03
Attorney Dkt No. 51278149		
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE VIA FACSIMILE		
<p>In re: application of: Theofanis C. Theofanidis Filing date: 03/20/2004 Serial No.: 10/811,822 Priority from co-pending PCT/US02/00476, filed 01/03/2002, co-pending US8N 08771,668, filed 01/03/2001, and US8N 08,086,707, filed 4/8/1998, now USPN 6,889,748, issued 24/02/2004 For: Composition For Protection Against Superficial Vasodilator Flush Syndrome</p> <p><u>Refiled Under 37 CFR 1.144</u></p> <p>Commissioner for Patents Box 1450 Alexandria, VA 22213-1450 Mail Stop: TC1800 Director Bruce Kellak</p> <p>Sir:</p> <p>Applicant is petitioning for reversal of the Examiner's restriction requirement initially mailed 05/04/2006, and maintained in her Office Action mailed 08/28/2006.</p> <p>The claims in question are set forth below. All of the claims are the original claims.</p> <p>40. A composition for protecting a subject from the inflammatory disease superficial vasodilator flush syndrome, said composition comprising a non- having heavily sulfated proteoglycan, ajoju kernel extract, a Flavonoid compound, bitter willow bark extract, and, optionally, cyproheptadine or azatidine.</p> <p>41. The composition of claim 40, wherein said proteoglycan is sulfated chondroitin sulfate.</p> <p>42. The composition of claim 40, wherein said flavonoid compound is quercetin, myricetin or genistein.</p> <p>43. The composition according to claim 1, wherein said inflammatory disease is superficial vasodilator flush syndrome, said composition comprising 60 mg non-</p>		

PAGE 40*RCVD AT 10/9/2006 10:00:04 PM [Eastern Daylight Time]*SVR:USPTO-EFXRF-37*DNN:2738300*CSID:2023628404*DURATION(mm:ss):01:48

RECEIVED
CENTRAL FAX CENTERAPR 12 2007
Attorney Dkt. No. 51275/149IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
VIA FACSIMILE**In re: application of:****Theoharis C. Theoharides****Filing date: 03/20/2004****Serial No.: 10/811,828****Priority from copending PCT/US02/00476, filed 01/03/2002,
copending USSN 09/771,669, filed 01/30/2001, and USSN 09/056,707, filed
4/8/1998, now USPN 6,689,748, issued 2/10/2004****For: Composition For Protection Against Superficial Vasodilator Flush Syndrome****Group Art Unit: 1655
Examiner: Patricia Leith**Petition Under 37 CFR 1.144

**Commissioner for Patents
Box 1450
Alexandria, VA 22313-1450
Mail Stop: TC1600 Director Bruce Kisliak**

Sir:

**Applicant is petitioning for reversal of the Examiner's restriction
requirement initially mailed 05/04/2006, and maintained in her Office Action
mailed 08/28/2006..**

**The claims in question are set forth below. All of the claims are the original
claims.**

**40. A composition for protecting a subject from the inflammatory disease
superficial vasodilator flush syndrome, said composition comprising a non-
bovine heavily sulfated proteoglycan, olive kernel extract, a flavonoid compound,
bitter willow bark extract, and, optionally, cyproheptadine or azatadine.**

**41. The composition of claim 40, wherein said proteoglycan is sulfated
chondroitin sulfate.**

**42. The composition of claim 40, wherein said flavonoid compound is quercetin,
myricetin or genistein.**

**43. The composition according to claim 1, wherein said inflammatory disease is
superficial vasodilation flush syndrome, said composition comprising 50 mg non-**

bovine chondroitin sulfate; olive kernel extract, 150-600 mg; 150-350 mg quercetin; 5% by weight bitter willow bark extract; and, optionally, 4 mg cyproheptadine or azatadine, administered daily.

44. A method of protecting against superficial vasodilator flush syndrome, comprising the oral administration of the composition of claim 40 or claim 43.

45. The composition of claim 1, wherein said syndrome is selected from the group consisting of carcinoid-induced flush, niacin-induced flush, mesenteric fraction syndrome-induced flush, and serotonin syndrome-induced flush.

As to the flavonoid component of generic claim 1, contrary to the examiner's assertion, all flavonoids have the same basic three-ring structure shown as Fig. 1 in applicant's traversal of 06/21/2006. The flavonoid species quercetin, myricetin and genestelin listed in claim 42 are merely claimed members of the same family. Looking at Fig. 2, also of record, it can be seen that quercetin and myricetin differ from each other only by a small functional group, namely, a hydroxyl group at R2. Looking at Fig. 3, also of record, it can be seen that genestelin has the same empirical formula as quercetin. All known members of the family of flavonoids have, contrary to the examiner's assertion, the same pharmacological, and differ only in relative strength. The examiner has shown no evidence to the contrary. Hence, applicant submits that this restriction requirement was made in error, and petitions the Director to reverse it.

The examiner has also ruled that the heavily sulfated proteoglycan component of composition claim 40 is too broad, and has ruled that applicant must limit this component to the chondroitin sulfate recited in claim 41. The applicant traversed by a showing that chondroitin sulfate is merely one of a family of molecules more accurately called "glycosaminoglycans" because one of the two sugars is always an amino sugar, e.g., N-acetylglucosamine. Other members of this family are listed and described in the accompanying e-articles with the URLs of <http://biol.lancs.ac.uk/gig/pages/pgnpage.htm> and <http://biol.paisley.ac.uk/courses/stfunmac/glossary/proteoglycan.htm>. All

sulfated proteoglycans are generally known in the art to exhibit similar properties, that include cartilage formation and joint lubrication. In the present invention, sulfated proteoglycans are shown to have anti-inflammatory effects. Thus, a search for "sulfated proteoglycans" will uncover chondroitin sulfate and other glycosaminoglycans suitable for practicing this invention. Applicant submits that it would be appropriate for the Director to withdraw this restriction requirement.

The Director is also respectfully reminded that there is an Office Action pending in this application.

Respectfully submitted,


Dr. Melvin Blecher
Attorney-at-Law
Registration No. 33,649

10/9/2006

**Law Offices of Dr. Melvin Blecher
4329 Van Ness St., NW
Washington, DC 20016-5625
Tel: 202 363 3338/0373
FAX: 202 362 8404
e-mail: MBiplaw@comcast.net**

TRANSMISSION VERIFICATION REPORT

TIME : 18/09/2026 00:23
NAME : MBIPLAW
FAX : 2023628404
TEL : 2023633338
SER. # : BR0F3J494063

DATE, TIME	10/09 00:22
FAX NO. /NAME	5712738300
DURATION	00:00:52
PAGE (S)	03
RESULT	OK
MODE	STANDARD ECM